Skip to content
    MMS
    Earnings call· Jun 2026(Q3 FY26)

    MAXIMUS Q3 FY26 earnings call MMS

    Aug 6, 2026 Source

    Executive summary

    Maximus Q3 FY26 — Strong Execution Amidst VA MDE Incentive Pause

    Maximus delivered strong Q3 FY26 results, marked by margin improvement and increased adjusted EPS, despite a customer-directed pause in performance incentives for the VA MDE program impacting the near-term outlook. The company is navigating procurement delays in the federal civilian market while seeing momentum in AI-enabled solutions, SNAP, and defense, and remains focused on strategic capital deployment and long-term growth.

    Highlights

    5
    • Adjusted EBITDA margin improved to 15.0% in Q3 FY26 from 14.7% in the prior year period.

    • Adjusted EPS increased to $2.22 in Q3 FY26 from $2.16 in the prior year period.

    • Collections from a major federal customer accelerated, with approximately $245 million received since June 30.

    • Repurchased approximately 0.75 million shares totaling $50 million in Q3 FY26.

    • Balance of awarded but not yet signed contracts stepped up to $1.35 billion, driven primarily by successful longer-term recompete activity.

    Concerns

    4
    • Customer-directed pause in performance incentives on the VA MDE program is expected to reduce Q4 FY26 diluted EPS guidance by approximately $0.35.

    • DSO remained elevated at 98 days in Q3 FY26 due to administrative delays at a major federal customer.

    • Full-year FY26 revenue guidance was reiterated with a bias towards the lower end of the $5.2 billion to $5.35 billion range.

    • Procurement delays, scope revisions, or cancellations in the federal civilian market are causing opportunities to mature more slowly.

    Guidance & targets

    15
    CategoryTargetConfidence
    Full-year FY26 Revenue
    $5.2 billion to $5.35 billion
    high materiality
    Medium
    Full-year FY26 Adjusted Diluted EPS
    $7.90 and $8.20 per share
    high materiality
    Medium
    Full-year FY26 Adjusted EBITDA Margin
    approximately 13.7%
    high materiality
    Medium
    Full-year FY26 Free Cash Flow
    $425 million and $475 million
    high materiality
    Medium
    Full-year FY26 U.S. Federal Services Segment Operating Margin
    16.5% and 17.0%
    medium materiality
    Medium
    Q4 FY26 U.S. Federal Services Operating Margin
    14.5% and 15.0%
    medium materiality
    Medium
    Full-year FY26 U.S. Services Segment Operating Margin
    9.5% to 10.0%
    medium materiality
    Medium
    Full-year FY26 Outside the U.S. Segment Operating Profit
    breakeven
    medium materiality
    Medium
    Full-year FY26 Interest Expense
    roughly $88 million
    low materiality
    Medium
    Full-year FY26 Tax Rate
    24% and 24.5%
    low materiality
    Medium
    DSO (Days Sales Outstanding)
    below 70 days
    medium materiality
    High
    VA MDE Incentive Pause Duration
    continues through December 31, 2026
    high materiality
    Medium
    U.S. Services Segment Organic Revenue Growth
    positive mid-single-digit organic growth
    medium materiality
    High
    Q4 FY26 Adjusted Diluted EPS
    $1.91
    high materiality
    Medium
    Q4 FY26 Adjusted EBITDA Margin
    approximately 13.7%
    high materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    U.S. Federal Services
    Revenue was in line with expectations. The prior year period benefited from elevated natural disaster support and temporary clinical volume surges. Operating income margin improved to 18.6% from 18.1% in the prior year, driven by efficiencies amidst solid volumes. The VA MDE incentive pause is expected to impact profitability starting Q4.
    $721 million18.6%
    U.S. Services
    Revenue was consistent with expectations to close the gap to prior year revenues. Operating income margin reflects solid upward progression. Positive mid-single-digit organic growth is anticipated in Q4 FY26 and into FY27, driven by Medicaid population activities.
    $418 million10.8%
    Outside the U.S.
    Revenue delta versus prior year was due to variances in volumes across several programs, including clinical and employment services. The segment recognized an operating profit of $1.2 million. The goal remains to drive growth and further margin improvement through successful conversion of the sales pipeline.
    $140 million$1.2 million

    Operational metrics

    16
    Adjusted EBITDA Margin
    15.0%up from 14.7% YoY
    Q3 FY26

    Driven by strong execution and selective deployment of efficiency-enhancing technology.

    Adjusted EPS
    $2.22up from $2.16 YoY
    Q3 FY26

    Increased compared to the prior year period.

    Cash Flows Used in Operating Activities
    $125 million
    Q3 FY26

    Outflow for the quarter.

    Days Sales Outstanding (DSO)
    98 days
    Q3 FY26

    Remained elevated due to administrative delays at a major federal customer.

    Collections from Major Federal Customer
    $245 million
    July 2026

    Received since June 30, indicating accelerated collections.

    Term Loan B Raised
    $325 million
    Q3 FY26

    Used to pay down revolver and provide additional flexibility for working capital.

    Total Debt
    $1.65 billionup from $1.55 billion as of March 31
    as of June 30, 2026

    Increased from prior quarter.

    Consolidated Net Total Leverage Ratio
    2.0xup from 1.8x in prior quarter
    as of June 30, 2026

    Remains within the stated target range of 2x to 3x.

    Shares Repurchased
    0.75 million
    Q3 FY26

    Part of opportunistic share repurchases.

    Amount Spent on Share Repurchases
    $50 million
    Q3 FY26

    Total amount spent on repurchases in the quarter.

    Remaining Share Repurchase Authorization
    $400 million
    as of June 30, 2026

    Entire amount from Board authorization in May remains available.

    Shares Repurchased Since FY25
    8.3 million14% of beginning outstanding shares
    since beginning of FY25

    Significant share count reduction over the period.

    AI in New Bids and Rebids
    75% to 80%
    current pipeline

    Percentage of pipeline opportunities containing explicit AI requirements or evaluation criteria.

    Operating Margin Improvement from AI
    3.5%
    current

    Achieved through AI-based improvements to core business processes like IVR and chatbot enhancement in specific contracts.

    Total Addressable Market (Defense-Related)
    nearly $47 billion
    long-term

    Identified as part of strategic planning, with only a small portion reflected in the reported pipeline.

    SNAP Payment Error Rate (National Average)
    10.6%compared to 10.9% in FY24
    FY25

    Indicates payment accuracy remains a significant challenge, reinforcing state interest in solutions.

    Orderbook & backlog

    9
    Total Pipeline Sales Opportunities$50.4 billionJune 30
    Proposals Pending$2.9 billionJune 30
    Proposals in Preparation$2.4 billionJune 30
    Opportunities Tracking$45.1 billionJune 30
    Share of New Work in Total Pipeline57%June 30
    U.S. Federal Services Segment's Share of Total Pipeline55%June 30
    Signed Contract Awards Year-to-Date$1.25 billionend of Q3 FY26

    Total contract value.

    Book-to-Bill Ratioapproximately 0.5xtrailing 12-month period

    Using standard reporting.

    Awarded but Not Yet Signed Contracts$1.35 billionJune 30

    significant step-up from last quarter

    Driven primarily by successful longer-term recompete activity; includes deals that have been through the protest process and successfully resolved.

    Product announcements

    2
    ProductTypeDetails
    Spectro Cloudexpansion
    Hackathon platformmilestone

    Deals & partnerships

    1
    Spectro CloudStrategic investment in an AI infrastructure management software provider.

    Maximus Ventures made a direct investment in Spectro Cloud. This partnership aims to bring differentiated capabilities to customers, including preferred access and co-development arrangements, to accelerate deployment, strengthen competitive position, support revenue growth, and increase customer value.

    Risks & headwinds

    4
    Temporary pause of performance incentives on VA MDE programEffective July 1, 2026, assumed to continue through December 31, 2026 (Q1 FY27).

    Reduces Q4 FY26 diluted EPS guidance by approximately $0.35.

    Mitigation: Maximus continues to deliver high-quality work and maintains a strong relationship with the VA; views it as an administrative action by the customer to improve their review process.

    Elevated Days Sales Outstanding (DSO)Q3 FY26.

    98 days in Q3 FY26.

    Mitigation: Collections from a major federal customer have accelerated in July, with $245 million received since June 30; expects DSO to be below 70 days by fiscal year-end.

    Procurement delays, scope revisions, or cancellations in the federal civilian marketCurrent.

    Opportunities maturing more slowly, leading to more bridge contracts and short-term extensions.

    Mitigation: Maintaining a disciplined, target-rich pipeline; underlying demand environment remains constructive.

    Complexity of CMS interim final rule for Medicaid work requirementsLess than 6 months until go-live date (January 1, 2027).

    Created additional uncertainty for states, slowing operationalization of compliance requirements.

    Mitigation: Underlying need for administrative support, beneficiary engagement, compliance monitoring, and technology enablement remains intact; Maximus is engaged with states and a recent court ruling affirmed implementation.

    What to watch in Q4 FY26

    5

    VA MDE incentive mechanism

    Q1 FY27 (after December 31, 2026)
    CurrentPaused, reducing Q4 FY26 EPS by $0.35.
    TargetReinstatement of incentives or clarity on successor contract structure.

    Why it matters

    Directly impacts the profitability of the U.S. Federal Services segment and overall earnings power.

    Our assumption based on customer guidance is the temporary pause continues through December 31, 2026. Therefore, we presume that in the first quarter of fiscal year 2027, we will not be eligible to earn incentives.

    Q&A highlights

    7

    Can you provide more color on the VA's decision to pause incentives and if this is an uncommon occurrence?

    Bruce Caswell explained that the VA's decision is a temporary pause to improve their internal review and validation process, not a reflection of Maximus's performance. He noted that while a significant contractual term suspension is not common, it's also not unprecedented for government contracts, and Maximus's model is to support customers through such changes.

    it's not uncommon for our customers to need to respond over the life of the contract... So while it's not common for a significant contractual term like this to be suspended, it's also not unprecedented.

    asked by Will Gildea · answered by Bruce L. Caswell

    3 min read6 chapters

    Detailed Narrative

    01

    VA MDE Contract Modification and Outlook

    The Department of Veterans Affairs (VA) implemented a temporary pause in performance incentives for the Medical Disability Exam (MDE) program, effective July 1, 2026. This action is expected to reduce Q4 FY26 diluted EPS by approximately $0.35 and is assumed to continue through December 31, 2026 (Q1 FY27). Management views this as an administrative measure by the customer to improve their review process, not a reflection of Maximus's performance, and maintains a strong relationship with the VA. A Draft Performance Work Statement (PWS) for the next contract has been released, indicating consistent scope and inclusion of all six regions, bolstering optimism for Maximus's position.

    02

    Federal Civilian Market Dynamics and Pipeline

    The federal civilian market is experiencing procurement delays, scope revisions, and occasional cancellations due to evolving priorities and budget considerations. This environment has led to an increase in bridge contracts and short-term extensions, causing opportunities to mature more slowly. Despite these challenges, the underlying demand environment remains constructive, with a total pipeline of $50.4 billion as of June 30, including $2.9 billion in proposals pending and $1.35 billion in awarded but unsigned contracts, which are expected to convert to signed contracts in subsequent quarters.

    03

    H.R. 1 Opportunities: Medicaid and SNAP

    Organic growth in the U.S. Services segment is expected to return in Q4 FY26, driven by increased beneficiary outreach for Medicaid. The complexity of the CMS interim final rule for Medicaid work requirements has slowed states' operationalization efforts, but a recent Federal District Court ruling affirmed the implementation of these requirements by January 1, 2027. SNAP opportunities are advancing more quickly, with significant customer interest in Maximus's Accuracy Assistant tool, driven by persistently high national payment error rates (10.6% in FY25) and upcoming administrative cost share increases for states.

    04

    Accelerated AI Adoption and Strategic Investments

    Maximus is actively integrating AI into its solutions and internal operations, with 75% to 80% of new bids and rebids in its pipeline containing explicit AI requirements. Internal AI-based improvements, such as IVR and chatbot optimization, have yielded a 3.5% operating margin improvement in five contracts. Through Maximus Ventures, the company made a direct investment in Spectro Cloud, an AI infrastructure management software provider, aiming to accelerate secure AI deployment for government customers, particularly in highly regulated defense areas.

    05

    Defense and National Security Market Expansion

    The defense and national security market is a priority for long-term growth, characterized by strong demand signals and an addressable market of nearly $47 billion. Maximus is expanding its capabilities and market presence, demonstrating success with key wins at the Air Force and Transportation Security Administration. The company believes that large government customers are increasingly willing to consider capable alternatives outside the traditional provider ecosystem, creating opportunities for differentiated companies with proven execution.

    06

    Capital Allocation and Shareholder Returns

    Maximus's capital allocation priorities include organic investments, a growing dividend, M&A opportunities, and opportunistic share repurchases. The company repurchased 0.75 million shares totaling $50 million in Q3 FY26, with $400 million remaining under authorization. Since FY25, Maximus has repurchased 8.3 million shares, representing about 14% of beginning outstanding shares. M&A efforts are focused on expanding capabilities, customer access, and driving long-term organic growth, while maintaining discipline on valuation and leverage targets (2x to 3x net debt ratio).

    AI-generated summary of the company’s earnings call. Not investment advice.